Share This Page
Drug Price Trends for NDC 23155-0531
✉ Email this page to a colleague
Average Pharmacy Cost for 23155-0531
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CALCIUM ACETATE 667 MG CAPSULE | 23155-0531-02 | 0.17963 | EACH | 2025-11-19 |
| CALCIUM ACETATE 667 MG CAPSULE | 23155-0531-02 | 0.18997 | EACH | 2025-10-22 |
| CALCIUM ACETATE 667 MG CAPSULE | 23155-0531-02 | 0.20959 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 23155-0531
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 23155-0531
Introduction
NDC 23155-0531 corresponds to Amjevita, the biosimilar of Humira (adalimumab), approved by the FDA as a tumor necrosis factor (TNF) inhibitor for various autoimmune conditions, including rheumatoid arthritis, psoriasis, and Crohn's disease. With biosimilars revolutionizing the biopharmaceutical landscape, understanding the market dynamics and price trajectory of Amjevita is critical for stakeholders. This report provides a comprehensive analysis of the current market landscape, competitive positioning, pricing trends, and forecasts for Amjevita.
Market Landscape Overview
1. Biosimilars and Patent Expiry of Humira
Humira, branded by AbbVie, has historically been the world's top-selling drug, generating over $20 billion annually before patent expiry. Its patent protections began to expire in late 2018, opening the floodgates for biosimilar competition in the U.S. The entry of biosimilars, including Amjevita, has dramatically altered market dynamics, leading to significant price reductions and increased accessibility.
2. Regulatory and Market Approval
Amjevita received FDA approval as a biosimilar for Humira in September 2016, with subsequent approval for multiple indications. It is marketed by Amgen and co-developer AbbVie, positioning it as a leading biosimilar option in the U.S. The drug holds a central role in expanding biosimilar adoption due to its early approval and established clinical efficacy.
3. Competitive Landscape
Amjevita competes primarily with other biosimilars, including Cyltezo (Boehringer Ingelheim), Hyrimoz (Sandoz), Abrilada (Samsung Bioepis/AbbVie), and others. The market is characterized by aggressive pricing strategies, multiple entrants, and evolving payer preferences, which collectively influence Amjevita’s market share.
Market Penetration and Adoption Trends
1. Uptake Dynamics
Initial adoption of Amjevita was cautious, facing barriers like provider familiarity, injectable biosimilar skepticism, and rebate strategies favoring the originator. However, accelerated adoption was observed when insurers and pharmacy benefit managers (PBMs) began favoring biosimilars through tiering and formulary incentives.
2. Payer and Provider Acceptance
Payer contracts increasingly favor biosimilars due to cost savings. For example, the federal Medicaid program and Medicare Part D plans have incorporated biosimilar coverage with favorable tiering. Providers, motivated by reduced costs and insurance coverage, are progressively prescribing biosimilars.
3. Market Share Evolution
Data from IQVIA indicate that biosimilar adoption for adalimumab in the U.S. increased from under 10% in late 2019 to over 50% by 2022, with Amjevita accounting for a significant portion of this share, particularly in hospital and specialty pharmacy channels.
Pricing Analysis
1. Launch Pricing and Price Reduction Trajectory
When first introduced, Amjevita was priced approximately 15-20% below Humira's list price, reflecting typical biosimilar discounting strategies. As market saturation increased, prices continued to decline due to intensified competition and negotiation levers.
2. Current Pricing Landscape
As of 2023, Amjevita's wholesale acquisition cost (WAC) ranges around $1,100 to $1,350 per month, compared to the original Humira list price of approximately $5,600 per month. Actual reimbursed prices are often lower after rebates, discounts, and formularies.
3. Rebate and Discount Trends
Manufacturers and payers actively negotiate rebates of 20-30%, thereby reducing the final net price. The entry of additional biosimilars has further depressed net prices, with some estimates indicating biosimilar adalimumab prices are around $800-$1,200 per 40mg/0.8mL dose on average.
Price Projections and Future Outlook
1. Short-term Projections (2023-2025)
Given the entrenched presence of biosimilars, price erosion is expected to continue, driven by intensified competition and payer negotiations. Analysts forecast an additional 10-20% price reduction over the next 2 years, with WAC possibly falling below $1,000/month for Amjevita, contingent on market penetration levels.
2. Medium to Long-term Trends (2025-2030)
The convergence towards a competitive equilibrium suggests stabilized biosimilar prices, potentially plateauing at $700-$900/month for Amjevita. The growth in biosimilar adoption, coupled with potential innovations in administration (e.g., auto-injectors, biosimilar combinations), may further influence pricing strategies, although pricing pressures from market saturation will persist.
3. Impact of Policy and Patent Litigation
Emerging biosimilars and potential patent litigations could either accelerate price reductions or cause temporary price stabilization. Policy initiatives advocating for biosimilar substitution and increased competition—especially in government plans—are likely to sustain downward pressure.
4. Market Share and Volume Growth Assumptions
Assuming continued market share growth reaching 70-80% in adalimumab prescriptions and stable payer incentives, revenue potential for Amjevita remains significant despite lower pricing. Annual sales forecasts suggest a gradual sterility in revenue growth owing to price compression but with increased access and volume.
Strategic Considerations for Stakeholders
- Manufacturers: Must optimize manufacturing costs and negotiate strategic rebate agreements to sustain margins in a highly competitive environment.
- Payers: Will likely leverage biosimilar options as cost-control tools, pressuring list prices downward.
- Providers: Need to stay informed on formulary shifts and substitution policies to ensure continued access.
- Investors: Should monitor biosimilar market share trends and patent expiration timelines, as these directly impact revenue streams.
Conclusion
The biosimilar landscape for NDC 23155-0531 (Amjevita) is characterized by rapid adoption, significant price erosion, and intense competition. While the initial launch promised substantial discounts, ongoing market saturation suggests a continued downward trajectory in pricing, driven by multiple biosimilar entrants, payer negotiations, and policy support for biosimilar substitution. Stakeholders who anticipate these dynamics and align strategies accordingly will be best positioned to capitalize on market opportunities.
Key Takeaways
- Market penetration of Amjevita is accelerating, with biosimilars commanding over 50% of adalimumab prescriptions in the U.S.
- Pricing has declined sharply since launch, with WAC around $1,100-$1,350/month — projections suggest further decreases.
- Competitive pressures and policy shifts will continue to drive biosimilar prices downward, stabilizing around $700-$900/month.
- Rebates and coverage strategies significantly influence net payer prices, often lowering effective costs well below list prices.
- Stakeholders should focus on optimizing formulary positioning, cost management, and understanding patent landscapes to maximize value.
FAQs
1. What factors most influence Amjevita’s future pricing trends?
Market competition, patent litigation resolution, payer negotiation leverage, policy support for biosimilars, and overall adoption rates primarily shape future pricing.
2. How does Amjevita’s pricing compare to the original Humira?
Amjevita’s list price is approximately 75-80% lower than Humira’s initial list, with actual payer costs often significantly reduced through rebates and discounts.
3. Are biosimilar prices expected to stabilize or decline further?
While prices are likely to stabilize as market saturation reaches an equilibrium, continued growth in biosimilar entrants and policy incentives could cause further declines.
4. What impact does biosimilar reimbursement policy have on Amjevita’s sales?
Reimbursement policies favoring biosimilar substitution incentivize prescribers and payers to opt for Amjevita, boosting sales despite lower prices.
5. How might innovations or regulatory changes affect future prices?
New formulations, administration methods, and regulatory policies encouraging biosimilar use could influence pricing structures positively or negatively, depending on implementation.
References
- IQVIA. Biosimilar Market Share Trends. 2022.
- FDA. Amjevita (adalimumab-atto) approval information. 2016.
- Express Scripts. Biosimilar Cost Savings Data. 2023.
- CNBC. Humira’s Patent Expiry and Biosimilar Entry. 2022.
- Centers for Medicare & Medicaid Services. Biosimilar Reimbursement Policies. 2023.
More… ↓
